Artikelen door HollandBIO

Whitepaper – Demonstrating the Value of Drugs for Rare Diseases

Demonstrating the Value of Drugs for Rare Diseases – 8 Common Challenges and How to Address Them Before They Arise James Horscroft, Linda Murphy, Ann-Marie Chapman and Ron Akehurst, BresMed No matter how robust in design, clinical trials can never fully address the uncertainty surrounding the comparative effectiveness and safety of a novel product in […]

Excelya Welcomes The Clinical Company

Excelya, a leading contract research organization (CRO) specializing in clinical research, announced that three European CROs joined Excelya Group: Zeincro based in Central-Eastern & Southern Europe, The Clinical Company based in the Netherlands and Belgium and Koehler eClinical based in Germany. Together, they will be known as Excelya Group. This alliance will allow Excelya to […]

Cergentis appoints new CEO and Board members

Cergentis, a genomics company that develops and commercializes kits and services based on its proprietary Targeted Locus Amplification (TLA) technology, today announced the appointment of Joris Schuurmans as Chief Executive Officer and Dirk Pollet and Maja Sanders as Supervisory Board members. Novalis Biotech Incubation will invest in Cergentis’ growth potential. Incoming CEO Joris Schuurmans has […]

, , ,

Dutch Life Sciences Trend Analysis: Record year of venture financing

Biotechgate, the leading global biotech database, presents the annual Trend Analysis Report for the Dutch life sciences sector. The report shows a stable amount of life sciences companies and a sector which has grown in maturity. Biotech companies were successful in attracting venture capital; 2019 is a record year for venture financing. Dutch biotech companies […]

Kiadis announces first patient enrolled with off-the-shelf K-NK cells

Kiadis Pharma, a clinical stage biopharmaceutical company, and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital (OSUCCC-James), today announced that the first patient has been enrolled and treated in a phase I, first-in-human clinical trial in patients with relapsed/refractory acute myeloid leukemia (“R/R AML”) with off-the-shelf Natural Killer (“NK”) cells […]

BISC Global opens an office in San Francisco

BISC Global is pleased to announce the opening of a new branch in South San Francisco, California. The new location complements the global presence with its current offices in Belgium, Boston and Switzerland. “We are thrilled to be expanding our footprint into the technology hub that is the Bay area” said Maarten Braspenning, CEO of […]

,

Update wijziging Wgp en modernisering GVS

De herijking van de maximumprijzen op grond van de Wet geneesmiddelenprijzen (Wgp) per 1 oktober 2020 gaat gepaard met twee mitigerende maatregelen, zo laat VWS-minister van Rijn de Kamer weten in een Kamerbrief. Met deze maatregelen beoogt de minister risico’s op beschikbaarheidsproblemen te verkleinen en de geneesmiddelenmarkt, gezien de COVID-19-crisis, niet extra te belasten. De […]

,

Access to COVID-19 Tools (ACT) Accelerator publishes consolidated plans

No-one is safe until everyone is safe. To end the ongoing COVID-pandemic, a groundbreaking global response is required. By drawing on the experience of leading global health organizations, governments, businesses, civil society and philanthropists the Access to COVID-19 Tools (ACT) Accelerator aims to accelerate the development, production, and equitable access to COVID-19 diagnostics, therapeutics, and […]

Hansa Biopharma receives positive CHMP opinion for Idefirix for kidney transplant in EU

Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending conditional approval of IdefirixTM (imlifidase) for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive […]